Browse the evidence

Fecal microbiota transplantation (FMT) from lean donors transiently improves insulin sensitivity and glucose metabolism in patients with metabolic syndrome, though effects often diminish after 18 weeks without maintenance.

FMT from lean donors can significantly boost insulin sensitivity and lower blood sugar in metabolic syndrome patients, but these benefits are temporary (lasting ~6 weeks) and may require repeated treatments or maintenance fiber. It is not a one-time cure and is currently expensive.

GLP-1 receptor agonists (GLP-1RAs) provide superior renal protection compared to insulin in early-stage diabetic kidney disease by reducing CD36 levels and urinary albumin excretion.

If you have type 2 diabetes and early kidney disease, ask your doctor about GLP-1 receptor agonists. They may protect your kidneys better than insulin while you continue taking metformin.

Whey protein supplements do not consistently provide superior body composition or strength benefits compared to whole milk or milk powder, and may carry risks of insulin resistance due to high branched-chain amino acid content.

You likely do not need expensive whey protein powder to build muscle. Whole milk or milk powder provide similar muscle-building benefits at a much lower cost and with additional nutritional advantages.

Menstrual cycle phase and oral contraceptive use do not significantly influence exercise performance or muscular hypertrophy in response to resistance training.

Train consistently regardless of your cycle phase. There is no evidence that you will lose muscle gains or performance by training during your luteal phase or while on birth control. Focus on progressive overload and consistency rather than phase-specific modifications.

PP protects against beta-cell apoptosis and may improve insulin sensitivity by enhancing the availability of insulin receptors.

PP may protect beta-cells and improve insulin sensitivity, suggesting potential anti-diabetic benefits.

GLP-1 receptor agonists (specifically exenatide) reduce fat mass and energy intake in HO patients but do not significantly alter BMI compared to placebo in the short term, and may decrease total energy expenditure.

Exenatide may help reduce fat mass and waist size in HO, but it often fails to lower BMI significantly. It is not a magic bullet for HO and requires careful monitoring for side effects like nausea.

Setmelanotide (MC4R agonist) is effective in reducing hunger and BMI in patients with HO due to hypothalamic injury, particularly those with specific genetic defects or structural damage affecting the melanocortin pathway.

Setmelanotide is a promising new treatment for HO that targets the root cause (MC4R deficiency). It requires daily injections and may cause skin darkening, but it is one of the few treatments showing efficacy in reducing BMI in this specific population.

Exogenous administration of undercarboxylated osteocalcin (ucOC) improves whole-body and skeletal muscle glucose metabolism and insulin sensitivity in animal models, though human evidence remains discordant.

Current research suggests that bone-derived factors like osteocalcin may help regulate blood sugar, especially in muscle. However, because human studies are inconsistent, there is no specific protocol to manipulate osteocalcin levels for diabetes treatment yet. Focus on proven methods: exercise (which naturally increases ucOC) and maintaining healthy bone density.

Sclerostin levels are elevated in individuals with Type 2 Diabetes and insulin resistance, and blocking sclerostin signaling improves insulin sensitivity in animal models.

High levels of sclerostin are linked to insulin resistance. While drugs targeting sclerostin (like romosozumab) exist for osteoporosis, their metabolic benefits are still being studied. For now, exercise and weight management remain the best ways to improve insulin sensitivity.

GLP-1 receptor agonists (specifically exenatide) reduce body fat and waist circumference in patients with hypothalamic obesity, with greater adiposity reduction observed in those with more extensive hypothalamic damage.

For patients with hypothalamic obesity, weekly exenatide injections (2 mg) can significantly reduce body fat and waist circumference, even if BMI changes are modest. This treatment is particularly effective for those with severe hypothalamic damage, likely because it works through brain pathways outside the damaged area. Side effects are mostly gastrointestinal.

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, reduces hunger and BMI in patients with hypothalamic obesity caused by acquired hypothalamic injury, marking a potential breakthrough for this condition.

Setmelanotide is an MC4R agonist that reduces hunger and BMI in patients with hypothalamic obesity. It is FDA-approved for genetic obesity and is showing effectiveness for acquired hypothalamic injury. A large Phase 3 trial is currently underway.

Skeletal muscle regeneration efficiency is time-of-day dependent, with injury occurring during the active phase (when satellite cell BMAL1 expression peaks) resulting in enhanced repair compared to injury during the inactive phase.

If you sustain a muscle injury or undergo strenuous exercise that causes damage, your body repairs the tissue more effectively during your active phase (typically daytime for humans). This is driven by satellite cell clocks peaking in activity (BMAL1) during this time. While you cannot control the injury, scheduling intense training sessions during your active phase may theoretically support faster or more robust repair compared to late-night sessions, though human data is still emerging.

Cry2 is critical for the circadian regulation of myogenic differentiation and fusion by maintaining Cyclin D1 expression and Tmem176b rhythmicity.

Cry2 helps coordinate the timing of muscle fiber fusion after injury. It ensures that cells don't exit the cell cycle too early and maintains the expression of genes needed for fibers to merge. Disruption of this clock component can lead to incomplete regeneration.

Acupuncture acts as a multi-targeted therapy for obesity by modulating the neuro-endocrine-immune interplay, specifically by regulating hypothalamic neuropeptides (increasing POMC/alpha-MSH, decreasing NPY/AgRP), improving leptin sensitivity, and reducing chronic low-grade inflammation.

If standard diet and exercise efforts are stalled by biological barriers like leptin resistance or chronic inflammation, acupuncture may serve as a complementary multi-targeted therapy. It works by regulating appetite hormones and reducing inflammation. However, because techniques and acupoints vary widely, consistency and professional guidance are key.

Prescription medication-driven weight loss (mdWL) using GLP-1 agonists causes facial aesthetic changes including skin laxity, hollowed cheeks, and pronounced wrinkles, primarily affecting superficial and deep fat pads rather than bone or muscle.

If you are losing weight rapidly with prescription medications like Ozempic or Wegovy, expect changes in your face, such as sagging skin or hollow cheeks, due to fat loss in specific facial layers. This is a common side effect of the medication's mechanism, not a sign of poor health. To manage this, consult an aesthetic provider about timing treatments (like fillers or skin tightening) to coincide with your weight stabilization, rather than during active rapid loss. Avoid terms like 'Ozempic face' and focus on 'mdWL' management to reduce stigma.

Injectable antiresorptive drugs (zoledronate, denosumab, romosozumab) are superior to oral bisphosphonates for preventing bone loss in long-duration space missions because they bypass gastrointestinal side effects and offer potent, sustained suppression of bone resorption.

For long-duration space travel, injectable bone-preserving drugs (zoledronate, denosumab, romosozumab) are preferred over oral options due to better efficacy and lack of gastrointestinal side effects. These drugs suppress bone resorption effectively with rare side effects when used for short durations (1-2 years).

Muscle wasting in space is primarily driven by depressed protein synthesis rather than excessive protein breakdown, and anabolic steroids are ineffective without concurrent resistance exercise.

To prevent muscle loss in space, resistance exercise is essential. Anabolic steroids may help but are weak alone and only effective when combined with strength training. The primary countermeasure remains physical exercise.

Utilizing lipid panels (specifically triglycerides and LDL-C levels) serves as a valid clinical indicator for assessing insulin resistance.

Monitor lipid panels, particularly triglycerides and LDL-C, as they are strong indicators of insulin resistance. High HDL-C is associated with increased insulin sensitivity.

In asymptomatic adults, the presence of food-specific IgG antibodies (particularly mild-to-moderate positivity) is associated with a lower prevalence of overweight, hypertriglyceridemia, and abnormal fasting blood glucose compared to IgG-negative individuals.

If you are asymptomatic and undergo routine health checks, having food-specific IgG antibodies (especially mild-to-moderate levels) is common and may actually be associated with healthier metabolic profiles (lower risk of high triglycerides, high blood sugar, and overweight). Do not interpret a positive IgG test as a diagnosis of food intolerance or allergy without clinical symptoms; it may simply reflect immune tolerance.

In Type-2 diabetes patients, elevated BMI, fasting plasma glucose, insulin resistance, and triglycerides are independent risk factors for developing nonalcoholic fatty liver disease (NAFLD).

If you have Type-2 Diabetes, managing your liver health requires looking beyond just blood sugar. You must actively monitor and manage your Triglycerides, Insulin Resistance, and Body Weight. High levels of any of these significantly increase your risk of developing fatty liver, so regular lipid panels and insulin sensitivity checks are critical components of your diabetes care.

In individuals with type 2 diabetes who carry the haptoglobin (Hp) 2-2 phenotype AND have a history of cardiovascular disease, maintaining an HbA1c level of 8.0% or higher is associated with an increased risk of coronary artery disease compared to levels of 7.0-7.9%.

If you have type 2 diabetes, the haptoglobin 2-2 genetic variant, and a history of heart disease, keeping your HbA1c at 8.0% or higher may increase your risk of coronary events compared to keeping it between 7.0% and 7.9%. This highlights the importance of avoiding high blood sugar levels in this high-risk group.

Ketogenic diets are not recommended for patients with Type 1 Diabetes due to increased risks of hypoglycemia, diabetic ketoacidosis (DKA), and potential bone health issues.

Avoid ketogenic diets if you have T1D. The risk of diabetic ketoacidosis (DKA) and hypoglycemia is too high. Focus on balanced meals with nonstarchy vegetables, whole foods, and careful carbohydrate counting instead of extreme restriction.

Patients who use anti-obesity medications (AOMs) prior to bariatric surgery experience significant weight regain (average 18 kg) upon stopping the medication, yet this history does not negatively impact their expectations for surgical weight loss.

If you stop taking weight loss drugs like Ozempic before surgery, you will likely regain the weight you lost (average 18kg). However, this history does not mean surgery will fail. Your expectations for surgery should remain focused on long-term health, as your prior drug experience doesn't change your surgical goals or likely success.

Weight loss, whether intentional or unintentional, increases serum concentrations of lipophilic persistent organic pollutants (POPs) by releasing them from adipose tissue into circulation, potentially negating long-term cardiovascular benefits of weight loss in type 2 diabetes patients.

For individuals with type 2 diabetes, standard weight loss advice may have hidden costs due to the release of stored environmental pollutants. While weight loss improves short-term markers, it may not reduce long-term heart disease risk if these pollutants are released. Future management may need to consider how to minimize this release or its effects, rather than focusing solely on fat mass reduction.